Arthur DeCillis currently serves as the president of DeCillis Consulting LLC, a company that provides oncology strategic, medical, and operational consulting services to the pharmaceutical and biotechnology industries. Prior to forming his own consulting practice, Arthur was the Chief Medical Officer for Eleven Biotherapeutics (now known as Sesen Bio Inc.), a late-stage clinical company developing next-generation antibody-drug conjugate (ADC) therapies. Previously, Arthur was the Vice President of Clinical Research and then Vice President of Medical Affairs at Exelixis, Inc., an oncology-focused biotechnology company. Prior to this, Arthur served as Executive director of Phase 2 and Phase 3 Oncology Development at Novartis. He also served as the Group Director of Bristol-Myers Squibb. Arthur has been involved in the development of several commercial drug including Sprycel (dasatinib), Afinitor (everolimus), Farydak (panobinostat), and Cabometyx (cabozantinib).